A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD
Recruiting in Palo Alto (17 mi)
+64 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: GlaxoSmithKline
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of the study is to investigate the effect of fluticasone furoate/vilanterol Inhalation Powder on arterial stiffness compared with placebo and vilanterol over a 24-week treatment period in subjects with COPD and aortic pulse wave velocity of 11.0 m/s or above.
Research Team
GC
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Eligibility Criteria
Inclusion Criteria
COPD diagnosis defined by ATS/ERS
Former or current smoker
A measured aortic pulse wave velocity = or > 11.0 m/s at Screening
Treatment Details
Interventions
- Fluticasone Furoate (Corticosteroid)
- Placebo (Inhalation)
- Vilanterol (Bronchodilator)
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: vilanterolExperimental Treatment1 Intervention
Inhaled long acting beta-agonist
Group II: Fluticasone Furoate/VilanterolExperimental Treatment1 Intervention
Inhaled corticosteroid/long acting beta-agonist
Group III: placeboPlacebo Group1 Intervention
Placebo
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
GSK Investigational SiteSaint Charles, MO
GSK Investigational SiteCharlotte, NC
GSK Investigational SiteTraverse City, MI
GSK Investigational SiteAbingdon, VA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Trials
4834
Patients Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)